Insight

Erman Akkus: Prostate cancer screening: 2 studies of JAMA

Photo of Erman Akkus taken from mn.uio.no

Apr 11, 2024, 15:12

Erman Akkus: Prostate cancer screening: 2 studies of JAMA

Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:

”Prostate cancer screening: 2 studies of JAMA.

1. PSA screening and 15-year mortality. ‘CAP trial’.

Screening vs standard practice, Prostate cancer-specific mortality: 0.69% vs 0.78%, RR: 0.92 (95% CI, 0.85-0.99) P = .03
Detection of Gleason score ≤6, T1/T2 disease higher, but not gleason ≥7, T3, T4/N1/M1, tumors.
All-cause deaths did not differ.

2. Screening with PSA, Kallikrein Panel, and MRI. ‘ProScreen trial’.

Screening invitation vs not invatiation; screening by stepwise testing vs. not screening.
1 additional high-grade cancer per 196 men and 1 low-grade cancer per 909 men were detected by invitation.
In invitation group: -Participants (screening group), low-grade cancer 0.41% and high-grade 1.65 %
-Not-participants, low-grade cancer 0.1% and high-grade 0.6%.”

Source: Erman Akkus/X

Ankara University cancer CAP trial Erman Akkus high-grade cancer invitation group JAMA low-grade cancer MRI OncoDaily Oncology ProScreen Trial prostate cancer prostate cancer screening

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage